Evidence of the breast CSCs resistance is supported by a study in which tumor biopsies taken from patients with breast cancer during the 12-week chemotherapy treatment conducted increased CSC markers (CD44+/CD24-/low and MFSE) [125]. This evidence concerns the gene CD24 and breast carcinoma.